Sutro Biopharma, Inc. (STRO) stock
STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.26+0.09 (+0.88%)
Close on Nov 11, 2026Market cap $170.12MP/E –Yield –
Sutro Biopharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Sutro Biopharma's ebitda for the twelve months ending Jun 30, 2026 was -$139.99M. For fiscal 2025 it was -$151.04M. The highest annual figure on record is $7.03M in fiscal 2016.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$151.04M | – |
| FY2024 | Dec 31, 2024 | -$231.24M | – |
| FY2023 | Dec 31, 2023 | -$82.46M | – |
| FY2022 | Dec 31, 2022 | -$123.25M | – |
| FY2021 | Dec 31, 2021 | -$93.68M | – |
| FY2020 | Dec 31, 2020 | -$66.76M | – |
| FY2019 | Dec 31, 2019 | -$50.69M | – |
| FY2018 | Dec 31, 2018 | -$32.68M | – |
| FY2017 | Dec 31, 2017 | -$14.28M | -303.3% |
| FY2016 | Dec 31, 2016 | $7.03M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$28.63M | – |
| Q1 FY2026 | Mar 31, 2026 | -$28.38M | – |
| Q4 FY2025 | Dec 31, 2025 | -$36.43M | – |
| Q3 FY2025 | Sep 30, 2025 | -$46.56M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.45M | – |
| Q1 FY2025 | Mar 31, 2025 | -$66.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$63.39M | -241.2% |
| Q3 FY2024 | Sep 30, 2024 | -$66.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$46.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$54.83M | – |
| Q4 FY2023 | Dec 31, 2023 | $44.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -$42.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$44.45M | – |
| Q1 FY2023 | Mar 31, 2023 | -$40.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$47.69M | – |
| Q3 FY2022 | Sep 30, 2022 | -$19.77M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.98M | – |
| Q1 FY2022 | Mar 31, 2022 | -$37.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$33.72M | – |
| Q3 FY2021 | Sep 30, 2021 | -$33.56M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.69M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.72M | – |
| Q4 FY2020 | Dec 31, 2020 | -$23.67M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.65M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.36M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.08M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.57M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.50M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.49M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.13M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.14M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.04M | – |
| Q2 FY2018 | Jun 30, 2018 | -$10.97M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.54M | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.97M | – |
See a number that looks wrong?